NextCure, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-10.
NextCure, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 10, 2025. The filing reports $21.50M sold. Its industry group is Biotechnology. It names Michael Richman (Executive Officer, Director), Steven Cobourn (Executive Officer), David Kabakoff (Director) (SEC Form D, December 10, 2025).
Sell to companies like NextCure, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NextCure, Inc.
Free to see. No signup.
More on the people and the money behind NextCure, Inc., from the filings we hold.
Biotechnology raises by companies based in Maryland, filed within 90 days of this one, largest first.
Get an email when NextCure, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NextCure, Inc. raises, hires or launches. No email unless you switch it on.
Watch NextCure, Inc. →Get the full cited report on NextCure, Inc.
What the filing shows about NextCure, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NextCure, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $21.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Michael Richman is named as Executive Officer and Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Steven Cobourn is named as Executive Officer on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
David Kabakoff is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Elaine Jones is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
John Houston is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Stephen Webster is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Ellen Feigal is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Anne Borgman is named as Director on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Udayan Guha is named as Executive Officer on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Timothy Mayer is named as Executive Officer on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Sourav Kundu is named as Executive Officer on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
Kevin Shaw is named as Executive Officer on the Form D that NextCure, Inc. filed with the SEC on 10 December 2025, one of 12 people that filing names.
12 people named on the filing — 6 holding an executive role and 6 as directors only.
Named as of the 2025-12-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about NextCure, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NextCure, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NextCure, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NextCure, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind NextCure, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for NextCure, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/nextcure-inc-form-d-25000001